DCT
1:26-cv-00990
Gilead Sciences Inc v. Cipla Ltd
Key Events
Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Gilead Sciences, Inc. (Delaware)
- Defendant: Cipla Ltd. (India)
- Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
- Case Identification: 1:26-cv-00990, D. Del., 08/06/2026
- Venue Allegations: Venue is asserted as proper on the basis that Defendant is a foreign corporation subject to personal jurisdiction in the District of Delaware.
- Core Dispute: Plaintiff alleges that Defendant's submission of a New Drug Application under 21 U.S.C. § 505(b)(2) for a generic version of the HIV drug ODEFSEY® constitutes an act of infringement of six patents covering specific salt forms and manufacturing processes for the active ingredient tenofovir alafenamide (TAF).
- Technical Context: The technology concerns specific crystalline salt forms and manufacturing methods for tenofovir alafenamide, a prodrug of the antiviral tenofovir, which are designed to improve stability, purity, and commercial viability for use in HIV treatments.
- Key Procedural History: The complaint notes that some of the asserted patents were the subject of prior litigation between the parties from 2020 to 2022 concerning an Abbreviated New Drug Application (ANDA) for ODEFSEY®, which settled before trial.
Case Timeline
| Date | Event |
|---|---|
| 2011-08-16 | Priority Date for '065 and '769 Patents |
| 2011-10-07 | Priority Date for '386, '534, and '841 Patents |
| 2014-03-04 | '386 Patent Issued |
| 2014-06-17 | '065 Patent Issued |
| 2015-05-12 | '534 Patent Issued |
| 2015-06-17 | Priority Date for '028 Patent |
| 2016-01-01 | ODEFSEY® Approved by FDA (approx. year) |
| 2016-03-29 | '769 Patent Issued |
| 2016-05-24 | '841 Patent Issued |
| 2017-10-03 | '028 Patent Issued |
| 2020-01-01 | Prior "TAF ANDA Litigation" initiated (approx. year) |
| 2022-01-01 | Prior "TAF ANDA Litigation" settled (approx. year) |
| 2025-12-01 | Related Gilead suit against Cipla filed (approx. month) |
| 2026-06-25 | Cipla's Notice Letter dated |
| 2026-06-29 | Gilead receives Cipla's Notice Letter (no earlier than) |
| 2026-07-22 | Gilead receives documents from Cipla's 505(b)(2) Application |
| 2026-08-06 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 8,754,065 - "Tenofovir Alafenamide Hemifumarate"
The Invention Explained
- Problem Addressed: The HIV antiviral tenofovir is not orally bioavailable, necessitating the creation of prodrugs like tenofovir alafenamide (TAF) Compl. ¶19 While a monofumarate salt of TAF was known, the patent sought to create a form with improved properties for pharmaceutical development, such as better stability and an improved ability to purge impurities during manufacturing '065 Patent, col. 5:1-10 '065 Patent, col. 11:1-6
- The Patented Solution: The patent discloses and claims a specific salt form called tenofovir alafenamide hemifumarate, which consists of two molecules of the TAF prodrug and one molecule of fumaric acid '065 Patent, summary of the invention Compl. ¶23 This specific 2:1 stoichiometric ratio is alleged to provide superior thermodynamic stability, chemical stability, and process reproducibility compared to the previously known monofumarate (1:1) form '065 Patent, col. 11:1-10 '065 Patent, col. 11:36-44
- Technical Importance: Developing a stable, high-purity, and consistently manufacturable crystalline form of an active pharmaceutical ingredient is a critical step in creating a safe and effective commercial drug product.
Key Claims at a Glance
- The complaint asserts infringement of at least claim 1 Compl. ¶43
- Independent claim 1 consists of a single element:
- Tenofovir alafenamide hemifumarate.
- The complaint reserves the right to assert additional claims Compl. ¶43
U.S. Patent No. 9,296,769 - "Tenofovir Alafenamide Hemifumarate"
The Invention Explained
- Problem Addressed: As with the '065 Patent, this patent addresses the need for a stable and pure form of TAF suitable for pharmaceutical use. It particularly focuses on the challenge of controlling the presence of related impurities, such as the monofumarate form of TAF, which can arise during synthesis '769 Patent, col. 7:62-67
- The Patented Solution: The patent claims a composition of tenofovir alafenamide hemifumarate that is defined by a specific purity level-namely, containing less than about 5% by weight of the tenofovir alafenamide monofumarate impurity '769 Patent, claim 1 The patent asserts that the hemifumarate form has an "exceptional capability to purge" other diastereomeric impurities, enabling the creation of a drug substance that meets this high-purity standard '769 Patent, col. 10:37-44
- Technical Importance: For regulatory approval and patient safety, pharmaceutical compositions must meet stringent purity requirements, and inventions that enable the consistent removal of impurities are significant in drug manufacturing.
Key Claims at a Glance
- The complaint asserts infringement of at least claim 1 Compl. ¶51
- Independent claim 1 has two essential elements:
- A composition comprising tenofovir alafenamide hemifumarate.
- The composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate.
- The complaint reserves the right to assert additional claims Compl. ¶51
U.S. Patent No. 9,777,028 - "Co-Crystals, Salts and Solid Forms of Tenofovir Alafenamide"
- Technology Synopsis: This patent discloses additional novel salt and co-crystal forms of TAF beyond the hemifumarate form. The invention addresses the ongoing need to discover new solid forms of TAF with desirable pharmaceutical properties. The patent specifically claims, among others, the sesquifumarate salt form of TAF '028 Patent, claim 7
- Asserted Claims: At least claim 7 is asserted Compl. ¶59
- Accused Features: The complaint alleges, on information and belief, that Cipla's product will contain multiple forms of TAF fumarate, including the claimed TAF sesquifumarate Compl. ¶38 Compl. ¶59
U.S. Patent Nos. 8,664,386; 9,029,534; and 9,346,841 - "Methods for Preparing Anti-Viral Nucleotide Analogs"
- Technology Synopsis: These patents address the problem that TAF is difficult to manufacture at commercially viable levels due to its stereochemical complexity Compl. ¶¶20-22 They claim novel and more efficient chemical methods for synthesizing TAF that substantially increase the useful yield '386 Patent, abstract Compl. ¶22
- Asserted Claims: At least claim 1 of each patent is asserted Compl. ¶67 Compl. ¶74 Compl. ¶81
- Accused Features: The complaint alleges, based on Gilead's experience that it is difficult to produce TAF commercially without using its patented methods, that Cipla's product will likely be produced utilizing the claimed processes, thereby infringing under 35 U.S.C. § 271(g) Compl. ¶39
III. The Accused Instrumentality
Product Identification
- Cipla's R/F/TAF 505(b)(2) Product, which are oral tablets containing emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate Compl. ¶5
Functionality and Market Context
- The accused product is a proposed fixed-dose combination drug for the treatment of HIV-1 infection in adults and pediatric patients Compl. ¶40 It is designed to be bioequivalent to Gilead's ODEFSEY® product and seeks approval for the same indications Compl. ¶35 Compl. ¶40 The complaint alleges that Cipla seeks to market this product before the expiration of the patents-in-suit Compl. ¶33 The complaint includes a diagram of the chemical structure of tenofovir alafenamide (TAF), highlighting its three stereocenters Compl. ¶20
IV. Analysis of Infringement Allegations
U.S. Patent No. 8,754,065 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| Tenofovir alafenamide hemifumarate. | The complaint alleges on information and belief that although Cipla contends its product is TAF monofumarate, the processes used to prepare TAF fumarates can also produce TAF hemifumarate, and that Cipla's product will therefore contain the claimed hemifumarate form. | ¶38; ¶43 | col. 1:30-34 |
U.S. Patent No. 9,296,769 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A composition comprising tenofovir alafenamide hemifumarate | The complaint alleges on information and belief that Cipla's product will contain the claimed TAF hemifumarate form. | ¶38; ¶51 | col. 1:35-39 |
| wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate. | The complaint alleges infringement of claim 1, which includes this purity limitation. It does not provide specific facts regarding the purity level of the accused product but asserts that the product will infringe. | ¶51; ¶52 | col. 9:1-4 |
- Identified Points of Contention:
- Factual Question (Composition): A central point of contention will be the actual chemical composition of Cipla's product. The complaint's allegations regarding the presence of TAF hemifumarate are made "on information and belief" and are central to the infringement theories for the '065 and '769 patents Compl. ¶38 The case may turn on analytical chemistry evidence developed during discovery.
- Factual Question (Process): For the TAF Process Patents, a key dispute will be whether Cipla's manufacturing method practices the steps claimed in those patents. The complaint bases this allegation on Gilead's own experience and the difficulty of producing TAF commercially without the patented methods, suggesting this will be a point of significant discovery Compl. ¶39
V. Key Claim Terms for Construction
- The Term: "tenofovir alafenamide hemifumarate"
- Context and Importance: This term appears in the independent claims of both the '065 and '769 patents and is the basis of the infringement allegation. The dispute centers on whether Cipla's product, which it allegedly presents as TAF monofumarate, in fact contains the claimed "hemifumarate" form. The construction of this term may therefore be critical to determining infringement.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patents define the invention by its stoichiometric ratio. For example, the '065 Patent states that the invention provides tenofovir alafenamide hemifumarate "wherein the ratio of fumaric acid to tenofovir alafenamide is 0.5±0.1" '065 Patent, col. 2:40-43 A party may argue this language covers any mixture or composition that meets this overall chemical ratio, regardless of its specific crystalline structure.
- Evidence for a Narrower Interpretation: The patents provide detailed characterization data for a specific crystalline solid, including a specific X-ray powder diffraction (XRPD) pattern and differential scanning calorimetry (DSC) curve '065 Patent, FIG. 1 '065 Patent, FIG. 2 A party may argue that the term "tenofovir alafenamide hemifumarate" should be construed not merely as a chemical ratio but as the specific, stable crystalline solid form described and characterized in the specification.
VI. Other Allegations
- Indirect Infringement: The complaint alleges induced infringement for the composition patents, stating that upon approval, Cipla's product label will instruct physicians and patients to administer the drug for HIV-1 treatment, thereby encouraging infringing use Compl. ¶40 Compl. ¶45 Compl. ¶53 For the process patents, infringement is alleged under 35 U.S.C. § 271(g) for the importation into the U.S. of a product made by a patented process Compl. ¶67 Compl. ¶74 Compl. ¶81
- Willful Infringement: The complaint does not use the word "willful" but alleges that Cipla has knowledge of the patents-in-suit. For the '065 and '769 Patents, knowledge is alleged based on the prior "TAF ANDA Litigation" involving the same patents Compl. ¶45 Compl. ¶53 For the other asserted patents, knowledge is alleged based on notice provided by Gilead Compl. ¶61 Compl. ¶68 The prayer for relief requests a finding that the case is "exceptional" under 35 U.S.C. § 285, which is often associated with findings of willful infringement or litigation misconduct Compl. Prayer for Relief (g)
VII. Analyst's Conclusion: Key Questions for the Case
- A core evidentiary question of chemical identity: Does Cipla's proposed product, which it reportedly claims is TAF monofumarate, actually contain the claimed TAF hemifumarate and/or TAF sesquifumarate? The resolution of this factual question, likely through extensive analytical testing, will be dispositive for several of the asserted patents.
- An evidentiary question of manufacturing process: Does the confidential process Cipla uses to manufacture its product infringe any of the claims of Gilead's TAF Process Patents? Proving infringement under 35 U.S.C. § 271(g) often presents a significant evidentiary hurdle that will depend on the scope of discovery into Cipla's operations.
- A potential claim construction question of definitional scope: Will the term "tenofovir alafenamide hemifumarate" be interpreted broadly to cover any composition with a specific 2:1 stoichiometric ratio of TAF to fumaric acid, or will it be construed more narrowly to mean the specific crystalline solid form characterized by the XRPD and DSC data disclosed in the patent?
Analysis metadata
Loading Complaint
Suggested improvements